“Chang’an Project” launched in Xi’an

       The “Chang’an Project,”  a study of people at high risk of HBV-related liver cancer, was launched in Xi’an on February 18,2023, sponsored by China Liver Health. The principal investigator, Professor Dang Shuangsuo at the Second Affiliated Hospital of Xi’an Jiaotong University (Xibei Hospital), hosted the meeting with the support of Xiamen Amoytop.

       By observing the effect of individualized and precise treatment in people with a high risk of HBV-related liver cancer, the Chang’an Project investigated the effect of nucleotide analogs and interferon treatment on the risk of hepatocellular carcinoma in this population and then explored the realization of clinical technical specifications to help more hepatitis B patients reduce the risk of progressing cirrhosis and liver cancer.

       Li Mingyang, director of the China Liver, presented that the hepatitis B population is the largest among all types of viral hepatitis in China, with about 86 million people chronically infected; the disease burden is the heaviest, and the types of patients and treatment methods are relatively complex. Advancing the treatment observation of hepatitis B, a high-risk group for liver cancer is essential to reduce the occurrence of cirrhosis and liver cancer originating from hepatitis B infection.

Prof. Dang Shuangsuo of Second Affiliated Hospital of Xi’an Jiaotong University is hosting the meeting

        Professors and specialists from 28 hospitals in Shaanxi, Shanxi, Yunnan, Xinjiang, Qinghai, Gansu, Fujian, and other provinces attended the Kick-off Meeting.

        Professor Xue Hong’an of the Second Affiliated Hospital of Xi’an Jiaotong University said,“Welcome to Xi'an and gather at the Chang’an Project to bring long-lasting stability to hepatitis B patients.”

Prof. Li Yaping of Second Affiliated Hospital of Xi’an Jiaotong University 

introduces Chang’an Project Program and Guarantee Project

Prof. Geng Jiawei from the Yunnan 1st Hospital, Prof. Lu Qinghua from the 4th People’s Hospital of Qinghai Province, and Prof. Xu Guanghua from the Affiliated Hospital of Yan’an University said that Chinese medical experts have long experience in using long-acting interferon to treat hepatitis B. They expect that under Prof. Dang Shuangsuo’s leadership, the “Chang’an Project” will encourage the collaborating hospitals to pass on their experience and achieve further success.

Prof. Lin Shumei,the First Affiliated Hospital of Xi’an Jiaotong university, 

explained the assessment and treatment for people with a high risk of liver cancer

Experts from 28 hospitals attended the meeting: Prof. Lin Shumei from the First Affiliated Hospital of Xi’an Jiaotong university, Prof. Lin Yongmei from Hanzhong 3201 Hospital, Prof. Wu Shihong from Yuncheng Central Hospital, Prof. Cao Haifang from the Fourth People’s Hospital of Qinghai, Prof. Jia Xiaoli from Second Affiliated Hospital of Xi’an Jiaotong University, Prof. Wang Hongfeng from Xinjiang Hospital of Chinese Medicine, Prof. Fu Jianjun from Xi’an Central Hospital, Prof. Ning Bo from Baoji Central Hospital, Prof. Jiang Hong from Hanzhong Hospital, Prof. Li Yaping from the Second Affiliated Hospital of Xi’an Jiaotong and Linfen Central Hospital(Shanxi Province), and Professors from Ankang Central Hospital. Prof. Zhang Yiling from the Second Affiliated Hospital of Lanzhou University and Prof. Zhu Yueyong from the First Affiliated Hospital of Fujian Medical University attended the meeting online.

Prof. Dang Shuangsuo of the Second Affiliated Hospital of Xi’an Jiaotong University, who is in charge of the project, concluded that after the “Chang’an Project” was launched in Xi’an, the project will work to collect valuable Chinese data and help reduce the incidence of liver cancer and cirrhosis, benefiting the majority of hepatitis B patients in China, with the cooperation of experts all across China.

By the end of the meeting, Manager Zheng Jiehua, on behalf of the public welfare support unit Xiamen Amoytop, stated that he would invest more time, energy, and resources to support the “Chang’an Project” to achieve solid scientific results.

The technical support unit Beijing Scitop illustrated the project data.